Technology ID
TAB-892

Method for the Treatment of Multiple Sclerosis

E-Numbers
E-143-2002-0
E-143-2002-1
Lead IC
NINDS
Co-Inventors
Martin, Roland
Applications
Therapeutics
Research Materials
Diagnostics
Therapeutic Areas
Immunology
The invention relates to the discovery that humanized antibodies to the interleukin-2 receptor (IL-2R) such as (daclizumab) are effective in treating multiple sclerosis (MS). In particular, it has been discovered that patients who have failed to respond to therapy with interferon-beta show dramatic improvement when treated with daclizumab, with patients showing both a reduction in the total number of lesions and cessation of appearance of new lesions during the treatment period. Daclizumab is effective both in combination with interferon-beta and alone.

Request More Info

Licensing Contact:
Ano, Susan
susan.ano@nih.gov

Patents

  • US
    Provisional (PRV) 60/393,021
    Filed on 2002-06-28
    Status: Abandoned
  • Patent Cooperation Treaty
    (PCT) PCT/US02/38290
    Filed on 2002-11-27
    Status: Expired
  • US Patent 7,258,859
    Filed on 2003-06-27
    Status: Abandoned
  • Patent Cooperation Treaty
    Patent Cooperation Treaty Combined (PCT COMB) PCT/US2003/020428
    Filed on 2003-06-27
    Status: Expired
  • US Patent 7,575,742
    Filed on 2004-12-22
    Status: Abandoned
  • US Patent 8,454,965
    Filed on 2007-07-13
    Status: Abandoned
  • US
    Continuation (CON) 15/234,575
    Filed on 2016-08-11
    Status: Abandoned
  • US Patent 8,298,525
    Filed on 2009-03-10
    Status: Abandoned
  • US
    Continuation (CON) 14/792,432
    Filed on 2015-07-06
    Status: Abandoned
  • US
    Continuation (CON) 13/725,119
    Filed on 2012-12-21
    Status: Abandoned
  • US
    Continuation (CON) 13/475,688
    Filed on 2012-05-18
    Status: Abandoned
  • US Patent 8,636,997
    Filed on 2012-09-12
    Status: Abandoned
  • US
    Continuation (CON) 14/139,424
    Filed on 2013-12-23
    Status: Abandoned
  • US
    Continuation (CON) 14/487,012
    Filed on 2014-09-15
    Status: Abandoned
  • US
    Continuation (CON) 15/956,458
    Filed on 2018-04-18
    Status: Abandoned
  • US
    Continuation (CON) 16/132,852
    Filed on 2018-09-17
    Status: Abandoned

Collaborations

  • Licensing
Date Published